Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model.

Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, Martignetti JA.

Cancer Res. 2009 Jun 1;69(11):4733-41. doi: 10.1158/0008-5472.CAN-08-4282. Epub 2009 May 12.

2.

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA.

J Clin Invest. 2008 Aug;118(8):2711-21. doi: 10.1172/JCI34780.

3.

Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.

Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, Terzo EA, Choudhri A, Narla G.

Lung Cancer. 2009 Dec;66(3):292-7. doi: 10.1016/j.lungcan.2009.02.014. Epub 2009 Mar 28.

4.

Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.

DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA.

Clin Cancer Res. 2006 Jun 15;12(12):3730-9.

5.

A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer.

Chen H, Chen L, Sun L, Zhen H, Li X, Zhang Q.

Gastric Cancer. 2011 Oct;14(4):339-52. doi: 10.1007/s10120-011-0049-x. Epub 2011 May 3.

PMID:
21538018
6.

The role of KLF6 and its splice variants in cancer therapy.

DiFeo A, Martignetti JA, Narla G.

Drug Resist Updat. 2009 Feb-Apr;12(1-2):1-7. doi: 10.1016/j.drup.2008.11.001. Epub 2008 Dec 18. Review.

PMID:
19097929
7.

Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.

Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Martignetti JA.

Cancer Res. 2005 Jul 1;65(13):5761-8.

8.

A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response.

DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, Narla G.

Cancer Res. 2008 Feb 15;68(4):965-70. doi: 10.1158/0008-5472.CAN-07-2604. Epub 2008 Feb 4.

9.

KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.

Hatami R, Sieuwerts AM, Izadmehr S, Yao Z, Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, Germain D, Burstein D, Kirschenbaum A, DiFeo A, Foekens JA, Narla G.

Sci Transl Med. 2013 Jan 23;5(169):169ra12. doi: 10.1126/scitranslmed.3004688.

10.

Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing.

Vetter D, Cohen-Naftaly M, Villanueva A, Lee YA, Kocabayoglu P, Hannivoort R, Narla G, M Llovet J, Thung SN, Friedman SL.

Hepatology. 2012 Oct;56(4):1361-70. doi: 10.1002/hep.25810. Epub 2012 Aug 27.

11.

E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor.

DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE, Friedman SL, Walsh MJ, Martignetti JA.

Oncogene. 2006 Sep 28;25(44):6026-31. Epub 2006 May 15.

PMID:
16702959
12.

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.

Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL.

Gastroenterology. 2008 May;134(5):1521-31. doi: 10.1053/j.gastro.2008.02.015. Epub 2008 Feb 13. Erratum in: Gastroenterology. 2008 Jul;135(1):326.

13.

Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform.

Liang WC, Wang Y, Xiao LJ, Wang YB, Fu WM, Wang WM, Jiang HQ, Qi W, Wan DC, Zhang JF, Waye MM.

RNA Biol. 2014;11(7):845-54. doi: 10.4161/rna.29356. Epub 2014 Jun 12.

14.

NOXA-induced alterations in the Bax/Smac axis enhance sensitivity of ovarian cancer cells to cisplatin.

Lin C, Zhao XY, Li L, Liu HY, Cao K, Wan Y, Liu XY, Nie CL, Liu L, Tong AP, Deng HX, Li J, Yuan Z, Wei YQ.

PLoS One. 2012;7(5):e36722. doi: 10.1371/journal.pone.0036722. Epub 2012 May 9. Erratum in: PLoS One. 2012;7(8): doi/10.1371/annotation/a863b4b3-6d4c-447a-87e3-4d631ceb7a46.

15.

Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function.

Rodríguez E, Aburjania N, Priedigkeit NM, DiFeo A, Martignetti JA.

PLoS One. 2010 Sep 9;5(9). pii: e12639. doi: 10.1371/journal.pone.0012639.

16.

KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment.

Huh SJ, Chen YL, Friedman SL, Liao J, Huang HJ, Cavenee WK, Robertson GP.

J Natl Cancer Inst. 2010 Aug 4;102(15):1131-47. doi: 10.1093/jnci/djq218. Epub 2010 Jul 21.

17.

The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions.

Hanoun N, Bureau C, Diab T, Gayet O, Dusetti N, Selves J, Vinel JP, Buscail L, Cordelier P, Torrisani J.

J Hepatol. 2010 Nov;53(5):880-8. doi: 10.1016/j.jhep.2010.04.038. Epub 2010 Jul 23.

PMID:
20801538
18.

Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury.

Ghiassi-Nejad Z, Hernandez-Gea V, Woodrell C, Lang UE, Dumic K, Kwong A, Friedman SL.

Hepatology. 2013 Feb;57(2):786-96. doi: 10.1002/hep.26056. Epub 2012 Dec 6.

19.

Functional role of the KLF6 tumour suppressor gene in gastric cancer.

Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G.

Eur J Cancer. 2009 Mar;45(4):666-76. doi: 10.1016/j.ejca.2008.11.009. Epub 2008 Dec 26.

20.

Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma.

Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, Chan AM, Friedman SL, Feuerstein BG, Martignetti JA.

Int J Cancer. 2007 Sep 15;121(6):1390-5.

Supplemental Content

Support Center